|
Gear Up For The New Year!! Sign Up For Our Newsletter!! LCRD,DLLR,HGSI,NETL,GHDX,MYL
(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (NASDAQ: LCRD) LaserCard Corp., (NASDAQ: DLLR) Dollar Financial Corp., (NASDAQ: HGSI) Human Genome Sciences, Inc., (NASDAQ: NETL) NetLogic Microsystems, Inc., (NASDAQ: GHDX) Genomic Health, Inc., (NASDAQ: MYL) Mylan, Inc.
www.StockMarketingInc.com
To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com
email us!! info@StockMarketingInc.com or call 1-866-583-8960
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: LCRD - LaserCard Corp.)
LATEST NEWS!!
LaserCard to Speak on Global Secure ID Capabilities at Cardex 2009 Digital Identity CEO Forum
December 13--15, Cairo, Egypt
MOUNTAIN VIEW, Calif., Dec 11, 2009 -- LaserCard Corporation (Nasdaq: LCRD) is one of four international companies selected to present to senior Egyptian officials at The Digital Identity CEO Forum, to be held in conjunction with Cardex 2009 Digital Identity Assurance Conference and Expo, Middle East and Africa. Cardex 2009 will take place in Cairo, Egypt, December 13-15. LaserCard will also showcase its global capabilities in delivering secure government identity (ID) solutions at Cardex booth #4D4.
The Digital Identity CEO Forum for Egypt has invited government officials of Egypt, C-Level executives, and senior directors of leading technology providers to attend the forum to discuss solutions and opportunities for collaboration on key ID projects in Egypt. Potential projects include National ID, driver license, vehicle registration, and an electronic health care card.
Uwe Ludwig, Vice President of Sales EMEA at LaserCard, will present LaserCard's capabilities, references and value as a potential teaming partner for projects in Egypt, highlighting the Company's customized approach to secure identity programs. LaserCard's credentials, featuring unique optical security media technology, are used worldwide in major ID card programs such as the Saudi Arabia National ID and the US Green Card.
At the event, LaserCard will demonstrate its Biometric Verification System and LC73000 optical media card personalization solution. LaserCard will also feature its innovative, technology-inclusive design and manufacturing capabilities that enable the creation of customized, program-specific credentials. Additionally, Uwe Ludwig will chair the Digital Identity Forum panel (Session 4) on Vehicle Registration and RFID for Traffic Control, to be held Tuesday, December 15 from 10 a.m. to 12 p.m.
About LaserCard Corporation LaserCard Corporation, together with its subsidiaries, is a leading provider of secure ID solutions to governments and commercial clients worldwide. It develops, manufactures, and integrates LaserCard(R) optical memory cards, multi-technology cards, encoders, peripherals, smart and specialty cards, biometrics, and modular software. The Company's cards and systems are used in various applications, including citizen identification, border security, government service delivery, and facility access.
For more information, please go to www.lasercard.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: DLLR - Dollar Financial Corp.)
LATEST NEWS!!
Dollar Financial Corp. Announces Pricing of $600 Million 10a...oe% Senior Notes
BERWYN, Penn., Dec 11, 2009 -- Dollar Financial Corp. (NASDAQ: DLLR), a leading international diversified financial services company primarily serving unbanked and under-banked consumers for nearly 30 years, today announced the pricing of the $600 million aggregate principal amount of senior notes offered by its indirect wholly owned Canadian subsidiary, National Money Mart Company. The notes will pay interest semi-annually at a rate of 10.375% per annum. The notes will be fully and unconditionally guaranteed, on a senior unsecured basis, by Dollar Financial Corp. and certain of its current and future direct and indirect wholly owned U.S. and Canadian subsidiaries. The notes will be sold to qualified institutional buyers in accordance with Rule 144A and Regulation S under the Securities Act of 1933, as amended (the "Securities Act"). The offering is expected to settle on December 23, 2009, subject to customary closing conditions.
Dollar Financial Corp. intends to use a portion of the net proceeds of the offering to finance the previously announced acquisition by its wholly owned subsidiary, Dollar Financial Group, Inc., of Military Financial Services, LLC, and to prepay approximately $350 million of outstanding borrowings under the term loan portion of its senior secured credit facility. The remainder of the proceeds will be utilized for general corporate purposes, which could include funding additional growth opportunities.
This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the Notes and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which, or to any person to whom, such an offer, solicitation or sale would be unlawful. Any offers of the Notes will be made only by means of a private offering circular.
About Dollar Financial Corp.
Dollar Financial Corp. is a leading diversified international financial services company primarily serving unbanked and under-banked consumers. Its customers are typically service sector individuals who require basic financial services but, for reasons of convenience and accessibility, purchase some or all of their financial services from the Company rather than from banks and other financial institutions. To meet the needs of these customers, the Company provides a range of consumer financial products and services primarily consisting of check cashing, short-term consumer loans, pawn lending, Western Union money order and money transfer products, currency exchange, gold buying, reloadable VISA(R) and MasterCard(R) branded debit cards, electronic tax filing, and bill payment services.
At September 30, 2009, the Company's global store network consisted of 1,188 stores, including 1,032 company-operated financial services stores and 156 franchised and agent locations in the United States, Canada, United Kingdom, Republic of Ireland, and Poland. The financial services store network is the largest network of its kind in each of Canada and the United Kingdom and the second-largest network of its kind in the United States. The Company's customers, many of whom receive income on an irregular basis or from multiple employers, are drawn to the convenient neighborhood locations, extended operating hours and high-quality customer service. The Company's financial products and services, principally check cashing, money transfer, pawn lending and short-term consumer loan programs, provide immediate access to cash for living expenses or other needs. For more information, please visit the Company's website at www.dfg.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: HGSI - Human Genome Sciences, Inc.)
LATEST NEWS!!
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
ROCKVILLE, Md., Dec 11, 2009 -- Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 2009 Deutsche Bank Biotech Boston Confab will be webcast and may be accessed at www.hgsi.com A member of Human Genome Sciences' senior management team will present a corporate overview on Tuesday, December 15, 2009 at 1:05 pm EST.
Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the webcast will be available for several days after the live event.
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company's web site at www.hgsi.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: NETL - NetLogic Microsystems, Inc.)
LATEST NEWS!!
NetLogic Microsystems Reports Inducement Grants Under NASDAQ Marketplace Rule 5635
MOUNTAIN VIEW, Calif., Dec 11, 2009 -- NetLogic Microsystems, Inc. (NASDAQ:NETL), a worldwide leader in high-performance intelligent semiconductor solutions for next-generation Internet networks, today announced that on December 7, 2009 the compensation committee of the company's board of directors approved the grants to a total of 8 new employees of the company of restricted stock units representing the right to acquire up to 24,550 shares of common stock. The restricted stock units were granted as inducements material to employment under the company's 2008 New Employee Inducement Incentive Plan in accordance with NASDAQ Marketplace Rule 5635(c)(4).
About NetLogic Microsystems NetLogic Microsystems, Inc. (NASDAQ:NETL) is a worldwide leader in high-performance intelligent semiconductor solutions that are powering next-generation Internet networks. NetLogic Microsystems' best-in-class products perform highly differentiated tasks of accelerating complex network traffic to significantly enhance the performance and functionality of advanced 3G/4G mobile wireless infrastructure, data center, enterprise, metro Ethernet, edge and core infrastructure networks. NetLogic Microsystems' market-leading product portfolio includes high-performance multi-core processors, knowledge-based processors, content processors, network search engines, ultra low-power embedded processors and high-speed 10/40/100 Gigabit Ethernet PHY solutions. These products are designed into high-performance systems such as switches, routers, wireless base stations, security appliances, networked storage appliances, service gateways and connected media devices offered by leading original equipment manufacturers (OEMs). NetLogic Microsystems is headquartered in Mountain View, California, and has offices and design centers throughout North America, Asia and Europe. For more information about products offered by NetLogic Microsystems, call +1-650-961-6676 or visit the NetLogic Microsystems Web site at http://www.netlogicmicro.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: GHDX - Genomic Health, Inc.)
LATEST NEWS!!
Genomic Health Announces Results of Clinical Survey Showing Use of Oncotype DX(R) Changes Treatment Recommendations for Women With Lymph Node-Positive Breast Cancer, Leading to Overall Reduction in Chemotherapy
--- Results from Survey of Current Practice by 160 U.S. Oncologists Presented at CTRC-AACR San Antonio Breast Cancer Symposium -
SAN ANTONIO, Dec 11, 2009 -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a clinical survey evaluating the impact of the Oncotype DX(R) Recurrence Score(R) result on physicians' adjuvant treatment recommendations for patients with node-positive, hormone receptor-positive breast cancer. The findings, presented as a poster at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium (Abstract # 2031), demonstrated that physicians frequently changed treatment recommendations for breast cancer patients with 1-3 positive nodes after integrating Recurrence Score results.
Oncotype DX is a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer. This survey of 160 medical oncologists about their clinical experience with Oncotype DX in node-positive breast cancer was conducted through a voluntary web-based questionnaire, and found that treatment recommendations changed for half of the patients after obtaining a Recurrence Score result.
Specifically, in the 138 cases where the physician had a specific treatment recommendation before obtaining the Recurrence Score, recommended treatment changed from hormonal therapy plus chemotherapy to hormonal therapy alone in 46 patients (33 percent), and from hormonal therapy alone to hormonal therapy plus chemotherapy in 13 patients (9 percent). Other regimen changes such as treatment intensity were reported in 11 patients (8 percent). In these patients with node-positive disease, 72 (52 percent) of patients analyzed had a low Recurrence Score result (<18), 53 (38 percent) had an intermediate Recurrence Score result (18-30) and 13 (9 percent) had a high Recurrence Score result (greater than or equal to 31). Recommendations based on the Recurrence Score results led to an overall reduction in chemotherapy.
"The clinical experiences of these physicians underscore the value of using Oncotype DX for node-positive breast cancer patients as demonstrated in five previous studies including one published yesterday in the online version of The Lancet Oncology," said Ruth Oratz, M.D., Clinical Associate Professor of Medicine, New York University School of Medicine, and lead author of the study. "As someone who has used Oncotype DX for treatment planning with both node-negative and node-positive breast cancer patients, I believe this test is becoming standard practice for individualizing treatment in early stage breast cancer." In this survey of 160 patients with node-positive disease, median age was 61 years and 79 percent of patients were postmenopausal. Patients had either stage T1 (62 percent), T2 (35 percent) or T3 (3 percent) disease. One, two, three or four or more positive lymph nodes were reported in 69 percent, 18 percent, 6 percent and 3 percent of patients, respectively. Therefore, physicians reported use of the Oncotype DX Recurrence Score(R) result to plan treatment for node-positive disease most often in patients with 1-3 positive nodes and stage T1 or T2 disease.
"Results from this survey of current practice patterns indicate that oncologists who order Oncotype DX for patients with node-positive breast cancer use the results in a similar manner as they do for node-negative patients," said Steven Shak, M.D., Chief Medical Officer of Genomic Health.
About Oncotype DX(R) The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. The Oncotype DX breast cancer test has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. As of November 2009, more than 8,000 physicians have ordered more than 120,000 tests in over 50 countries, and both Medicare and private health plans covering over 90 percent of U.S. insured lives, provide reimbursement for Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit www.oncotypedx.com.
About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX(R) breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health is preparing to launch its Oncotype DX colon cancer test in the first quarter of 2010. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: MYL - Mylan, Inc.)
LATEST NEWS!!
ylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg
PITTSBURGH, Dec 11, 2009 -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 1000 mg. Levetiracetam Tablets are the generic version of UCB Pharma's antiepileptic Keppra(R). This additional strength of Levetiracetam Tablets complements Mylan's already approved and marketed strengths of 250 mg, 500 mg and 750 mg.
Levetiracetam Tablets, 1000 mg had U.S. sales of approximately $136 million for the 12 months ending Sept. 30 and is shipping immediately.
Currently, Mylan has 130 ANDAs pending U.S. Food and Drug Administration approval representing $85 billion in annual brand sales, according to IMS. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $19.2 billion in annual brand sales, according to IMS.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
About StockMarketingInc.com
StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To Homepage ]
|
